Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial

Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial

Summary: Background: There are an estimated 1·3–4·0 million cases of cholera and 20 000–140 000 cholera-related deaths worldwide each year. The rice-based cholera toxin B subunit (CTB) vaccine, MucoRice-CTB, is an oral candidate vaccine that does not require a cold chain, has shown efficacy in anim...

Full description

Bibliographic Details
Main Authors: Yoshikazu Yuki, PhD, Masanori Nojima, MD, Osamu Hosono, MD, Hirotoshi Tanaka, ProfMD, Yasumasa Kimura, PhD, Takeshi Satoh, PhD, Seiya Imoto, ProfPhD, Satoshi Uematsu, ProfMD, Shiho Kurokawa, PhD, Koji Kashima, PhD, Mio Mejima, PhD, Rika Nakahashi-Ouchida, PhD, Yohei Uchida, MS, Takanori Marui, MS, Noritada Yoshikawa, MD, Fumitaka Nagamura, ProfMD, Kohtaro Fujihashi, ProfDDS, Hiroshi Kiyono, ProfDDS
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:The Lancet Microbe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666524720301968

Internet

http://www.sciencedirect.com/science/article/pii/S2666524720301968

Similar Items